par De Bruyn, Pauline 
;Van Gestel, Dirk ;Ost, Piet;Kruse, Vibeke;Brochez, Lieve;Van Vlierberghe, Hans;Devresse, Arnaud;Del Marmol, Véronique ;Le Moine, Alain ;Aspeslagh, Sandrine
Référence Current opinion in oncology, 31, 2, page (54-64)
Publication Publié, 2019-02-01
;Van Gestel, Dirk ;Ost, Piet;Kruse, Vibeke;Brochez, Lieve;Van Vlierberghe, Hans;Devresse, Arnaud;Del Marmol, Véronique ;Le Moine, Alain ;Aspeslagh, SandrineRéférence Current opinion in oncology, 31, 2, page (54-64)
Publication Publié, 2019-02-01
Article révisé par les pairs
| Résumé : | Checkpoint inhibitors (CPIs) provide impressive response rates among immunocompetent patients with various solid tumors. So far, organ transplant recipients have been excluded from clinical studies due to the putative risk of allograft rejection however 48 cases of liver and renal transplant patients treated with CPI were already described in literature. |
